TY - JOUR
T1 - Immunomodulatory properties of a new hypoxantine derivative, PCF-39
T2 - I. Activation of mature phagocytes and modulation of NK cells
AU - Ponzoni, M.
AU - Melodia, A.
AU - Cirillo, C.
AU - Perezzani, L. S.
AU - Migliorati, G.
AU - Riccardi, C.
AU - Forni, G.
AU - Cornaglia-Ferraris, P.
PY - 1987
Y1 - 1987
N2 - The synthesis of the hypoxanthine derivative Nα-5 (1.6-dihidro-6-oxo-9-purinyl)pentyloxy/carbonyl-L-Arginine, PCF-39 is briefly described. In vitro, results herein presented indicate that PCF-39 modulates the phagocytic cells while being unable to induce terminal differentiation of human leukemic cells, U-937 and HL-60. The NK-activity is also down modulated in mice depending upon age and doses, while NK precursors growth appears to be faster and higher in BM transplanted animals. Data herein presented would confirm what has been previously postulated in immunosuppressed mice treated with PCF-39 before challenging it in several microbial and tumor graft models. Results would indicate that PCF-39 is an interesting synthetic immunomodifier in the family on the hypoxanthine derivatives endowed with immunomodulatory properties.
AB - The synthesis of the hypoxanthine derivative Nα-5 (1.6-dihidro-6-oxo-9-purinyl)pentyloxy/carbonyl-L-Arginine, PCF-39 is briefly described. In vitro, results herein presented indicate that PCF-39 modulates the phagocytic cells while being unable to induce terminal differentiation of human leukemic cells, U-937 and HL-60. The NK-activity is also down modulated in mice depending upon age and doses, while NK precursors growth appears to be faster and higher in BM transplanted animals. Data herein presented would confirm what has been previously postulated in immunosuppressed mice treated with PCF-39 before challenging it in several microbial and tumor graft models. Results would indicate that PCF-39 is an interesting synthetic immunomodifier in the family on the hypoxanthine derivatives endowed with immunomodulatory properties.
UR - http://www.scopus.com/inward/record.url?scp=0023575307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023575307&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0023575307
VL - 7
SP - 161
EP - 165
JO - EOS Rivista di Immunologia ed Immunofarmacologia
JF - EOS Rivista di Immunologia ed Immunofarmacologia
SN - 0392-6699
IS - 4
ER -